| Q41745036 | A Critical Role for Immune System Response in Mediating Anti-influenza Drug Synergies Assessed by Mechanistic Modeling |
| Q24187883 | Amantadine and rimantadine for influenza A in children and the elderly |
| Q24203853 | Amantadine and rimantadine for influenza A in children and the elderly |
| Q30366719 | Antiviral combinations for severe influenza. |
| Q30386119 | Avian influenza--a review for doctors in travel medicine. |
| Q92360533 | Bioavailability and Pharmacokinetics of Once-Daily Amantadine Extended-Release Tablets in Healthy Volunteers: Results from Three Randomized, Crossover, Open-Label, Phase 1 Studies |
| Q30394067 | Characterization of Oseltamivir-Resistant 2009 H1N1 Pandemic Influenza A Viruses |
| Q30408112 | Combination chemotherapy for influenza |
| Q37549382 | Combination therapy with amantadine, oseltamivir and ribavirin for influenza A infection: safety and pharmacokinetics |
| Q30398804 | Detection of resistance mutations to antivirals oseltamivir and zanamivir in avian influenza A viruses isolated from wild birds |
| Q92162215 | Effects of Renal Impairment on the Pharmacokinetics of Once-Daily Amantadine Extended-Release Tablets |
| Q28533778 | I222 Neuraminidase mutations further reduce oseltamivir susceptibility of Indonesian Clade 2.1 highly pathogenic Avian Influenza A(H5N1) viruses |
| Q28473743 | Influenza A H5N1 clade 2.3.4 virus with a different antiviral susceptibility profile replaced clade 1 virus in humans in northern Vietnam |
| Q28282405 | Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance |
| Q40138039 | Modelling the emergence of influenza drug resistance: The roles of surface proteins, the immune response and antiviral mechanisms |
| Q30456363 | Newer influenza antivirals, biotherapeutics and combinations |
| Q56785849 | Oseltamivir for treatment and prophylaxis of influenza infection |
| Q30386487 | Oseltamivir in human avian influenza infection. |
| Q30394541 | Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics. |
| Q30409023 | Oseltamivir in seasonal, pandemic, and avian influenza: a comprehensive review of 10-years clinical experience |
| Q38084212 | Pharmacokinetic properties of anti-influenza neuraminidase inhibitors |
| Q42622839 | Pharmacokinetics and safety of coadministered oseltamivir and rimantadine in healthy volunteers: an open-label, multiple-dose, randomized, crossover study |
| Q37115683 | Pharmacokinetics of high-dose oseltamivir in healthy volunteers |
| Q30397509 | Pharmacologic considerations for oseltamivir disposition: focus on the neonate and young infant |
| Q43072391 | Simultaneous determination of memantine and amantadine in human plasma as fluorescein derivatives by micellar electrokinetic chromatography with laser-induced fluorescence detection and its clinical application |
| Q27663966 | Structural and Functional Basis of Resistance to Neuraminidase Inhibitors of Influenza B Viruses |
| Q50925652 | Study on the abuse of amantadine in tissues of broiler chickens by HPLC-MS/MS. |
| Q36468109 | The status of pharmacometrics in pregnancy: highlights from the 3(rd) American conference on pharmacometrics |
| Q37975932 | Therapeutics against influenza |
| Q21142648 | Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro |
| Q30379095 | Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro. |